Table 1.

The CD13 expression and the clinicopathological features of GC patients.

CD13 expression
Clinico-pathological features	N	-	+	++	+++	PR(%)	P value
Age
≤50 years	55	18	15	15	7	67.2	0.76#
>50 years	65	19	10	23	13	70.7
Gender							0.67#
Male	56	20	15	15	12	73.3
Female	64	17	10	23	8	67.3
Tumor Differentiation							0.64#
Well	46	17	10	11	8	65.6
Moderately	36	9	8	14	5	75.6
Poor	38	11	7	13	7	71.0
Tumor Location							0.53#
Proximal	51	14	12	16	9	72.5
Distal	69	23	13	22	11	66.7
Clinical stages							0.46#
T1- T2	63	17	12	26	8	71.4
T3- T4	57	20	13	12	12	64.6
Nodal Metastasis							0.013∗∗
N0	62	12	14	20	16	80.8
N1-N3	58	25	11	18	4	56.9
Application of FOLFOX							0.009∗∗
Yes	65	9	6	31	19	86.1
No	55	28	19	7	1	49.0

PR(%): positive rate.

χ2 test was adopted to evaluate association between the clinical parameters with CD13 expression in GC patients.  ^∗P < 0.05,  ^∗∗P<0.01, and  ^#P > 0.05.